Free Trial
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

$64.97
0.00 (0.00%)
(As of 05/20/2024 ET)
Today's Range
$64.97
$64.97
50-Day Range
$34.91
$64.97
52-Week Range
$8.33
$65.00
Volume
N/A
Average Volume
1.92 million shs
Market Capitalization
$4.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.33

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
19.5% Downside
$52.33 Price Target
Short Interest
Healthy
5.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Alpine Immune Sciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1,227 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.74) to ($1.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

622nd out of 921 stocks

Pharmaceutical Preparations Industry

283rd out of 415 stocks

ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

ALPN Stock News Headlines

What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. (ALPN)
Alpine Immune Sciences soars on $4.9bn Vertex takeover
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
5/22/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.33
High Stock Price Target
$65.00
Low Stock Price Target
$18.00
Potential Upside/Downside
-19.5%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-64.99%

Debt

Sales & Book Value

Annual Sales
$58.88 million
Book Value
$4.85 per share

Miscellaneous

Free Float
39,581,000
Market Cap
$4.46 billion
Optionable
Optionable
Beta
0.97
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price target for 2024?

11 Wall Street analysts have issued twelve-month price targets for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $65.00. On average, they anticipate the company's share price to reach $52.33 in the next twelve months. This suggests that the stock has a possible downside of 19.5%.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 at the start of the year. Since then, ALPN shares have increased by 240.9% and is now trading at $64.97.
View the best growth stocks for 2024 here
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings results on Monday, March, 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.47. The biotechnology company had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 14.86% and a negative net margin of 65.17%.

What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Decheng Capital LLC (12.13%), Avoro Capital Advisors LLC (8.42%), Price T Rowe Associates Inc. MD (4.49%), Vanguard Group Inc. (4.14%), Darwin Global Management Ltd. (2.89%) and Vivo Capital LLC (0.79%). Insiders that own company stock include Decheng Capital China Life Sci, James N Topper, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALPN) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners